Buy Rating Affirmed for Capricor Therapeutics Amidst Positive FDA Discussions and Clinical Advancements

Capricor Therapeutics (CAPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $12.00 price target.

Jason McCarthy has given his Buy rating due to a combination of factors surrounding the positive progress of Capricor Therapeutics’ CAP-1002 program. His optimism is primarily rooted in the successful discussions with the FDA, which have set the stage for a potential accelerated Biologics License Application (BLA) filing. The positive outcome from the recent Type-B meeting and the confirmed comparability of CAP-1002 drug products manufactured at Capricor’s facilities further support his confidence in the stock. Moreover, the anticipated presentation of the three-year safety and efficacy data from the HOPE-2 study adds to the company’s robust clinical portfolio.
Additionally, the completion of the interim futility analysis for Cohort A in the HOPE-3 Phase 3 study, with positive feedback from the Data Safety Monitoring Board, underpins the potential for success in the ongoing trial. The strategic decision to focus on Cohort A for the BLA filing, thereby avoiding a two-year extension for additional patient enrollment, illustrates Capricor’s efficient use of resources and time. The $10M milestone payment received from the distribution and commercialization agreement with Nippon Shinyaku further highlights the financial and strategic achievements underpinning McCarthy’s Buy rating for Capricor Therapeutics.

In another report released on April 25, H.C. Wainwright also reiterated a Buy rating on the stock with a $40.00 price target.

CAPR’s price has also changed dramatically for the past six months – from $2.805 to $5.410, which is a 92.87% increase.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Capricor Therapeutics (CAPR) Company Description:

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.